{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-228145","form_type":"8-K","ticker":"APLS","cik":"0001492422","company_name":"Apellis Pharmaceuticals, Inc.","filed_at":"2022-08-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.908872+00:00","generated_at":"2026-06-23T21:42:30.557423+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Apellis reports 24-month Phase 3 data: pegcetacoplan shows increasing efficacy in GA","bullets":["At 24 months, monthly pegcetacoplan reduced GA lesion growth 19% in DERBY (p=0.0004) and 22% in OAKS (p<0.0001) vs sham.","Between months 18-24, treatment effect accelerated: DERBY monthly 36% (p<0.0001), OAKS monthly 24% (p=0.0080) reduction.","Safety profile consistent; infectious endophthalmitis rate 0.034% per injection, no occlusive vasculitis or retinitis over 24 months.","US PDUFA target action date Nov 26, 2022; EU marketing authorization application planned by end of 2022.","Key secondary visual function endpoints showed no clinically meaningful difference at 24 months, attributed to endpoint limitations."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-228145","json":"https://secwatch.observer/filing/0001193125-22-228145.json","markdown":"https://secwatch.observer/filing/0001193125-22-228145.md","text":"https://secwatch.observer/filing/0001193125-22-228145.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522228145/0001193125-22-228145-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1492422/000119312522228145/d305749d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:42:30.557423+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}